Patent Issued for Human antibodies to PCSK9 for use in methods of treating particular groups of subjects (USPTO 12083176).

A patent has been issued to Sanofi for human antibodies to PCSK9, a protein involved in cholesterol regulation. The patent describes the use of these antibodies in combination with statins, a common type of cholesterol-lowering medication, to enhance their effectiveness and reduce side effects. The inventors found that specific dosage regimens and patient groups benefit more from this combination therapy. The patent provides details on the composition and administration of the antibodies and their potential use in treating diseases related to PCSK9 expression or activity. [Extracted from the article]